Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Orfi

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 31, 2004
Comparison of measured and calculated lipophilicity of substituted aurones and related compoundsB Hallgas, T Patonay, A Kiss-Szikszai, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 28, 2007
Targeting of the VEGF-kinase inhibitor PTK787 to angiogenic vasculature using RGD-equipped albumin carrier moleculesK Temming, M Lacombe, H E Moorlag, et al.
British Journal of Pharmacology|September 30, 2009
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological propertiesC Hegedus, C Ozvegy-Laczka, A Apáti, et al.
Acta Pharmaceutica Hungarica|July 13, 1999
[Preparation and characterization of potential antineoplastic agents]L Orfi, F Wáczek, M Szabó, et al.
Current Medicinal Chemistry|December 15, 2010
Novel, selective CDK9 inhibitors for the treatment of HIV infectionG Németh, Z Varga, Z Greff, et al.
Current Medicinal Chemistry|March 11, 2014
Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitorsF Baska, I Szabadkai, A Sipos, et al.
Cancer Research|August 1, 1996
Flk-1 as a target for tumor growth inhibitionL M Strawn, G McMahon, H App, et al.
Current Medicinal Chemistry|November 11, 2008
Signalling inhibitors against Mycobacterium tuberculosis--early days of a new therapeutic concept in tuberculosisB Hegymegi-Barakonyi, R Székely, Z Varga, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 31, 2004
Comparison of measured and calculated lipophilicity of substituted aurones and related compoundsB Hallgas, T Patonay, A Kiss-Szikszai, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 28, 2007
Targeting of the VEGF-kinase inhibitor PTK787 to angiogenic vasculature using RGD-equipped albumin carrier moleculesK Temming, M Lacombe, H E Moorlag, et al.
British Journal of Pharmacology|September 30, 2009
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological propertiesC Hegedus, C Ozvegy-Laczka, A Apáti, et al.
Acta Pharmaceutica Hungarica|July 13, 1999
[Preparation and characterization of potential antineoplastic agents]L Orfi, F Wáczek, M Szabó, et al.
Current Medicinal Chemistry|December 15, 2010
Novel, selective CDK9 inhibitors for the treatment of HIV infectionG Németh, Z Varga, Z Greff, et al.
Current Medicinal Chemistry|March 11, 2014
Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitorsF Baska, I Szabadkai, A Sipos, et al.
Cancer Research|August 1, 1996
Flk-1 as a target for tumor growth inhibitionL M Strawn, G McMahon, H App, et al.
Current Medicinal Chemistry|November 11, 2008
Signalling inhibitors against Mycobacterium tuberculosis--early days of a new therapeutic concept in tuberculosisB Hegymegi-Barakonyi, R Székely, Z Varga, et al.
Pageof 3